The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EN | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors | |
| 5 | L01EN01 | Erdafitinib |
| Active Ingredient | Description | |
|---|---|---|
| Erdafitinib |
Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Erdafitinib increases serum phosphate concentration, a secondary effect of FGFR inhibition. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BALVERSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.